VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q89546812  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000218.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q89546812‏
024 ‎‡a  0000-0003-3220-6065‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q89546812‏
100 0 ‎‡a  Ling Wang‏ ‎‡c  researcher (ORCID 0000-0003-3220-6065)‏ ‎‡9  en‏
670 ‎‡a  Author's Comparisons of pharmacokinetics and NO-releasing of nitrofibriate and fenofibrate after oral administration in rats‏
670 ‎‡a  Author's Dose Adjustment of Quetiapine and Aripiprazole for Pregnant Women Using Physiologically Based Pharmacokinetic Modeling and Simulation‏
670 ‎‡a  Author's Enhanced Cancer-targeted Drug Delivery Using Precoated Nanoparticles‏
670 ‎‡a  Author's In-vitro and in situ assessment of the efflux of five antidepressants by breast cancer resistance protein‏
670 ‎‡a  Author's Metabolite identification, tissue distribution, excretion and preclinical pharmacokinetic studies of ET-26-HCl, a new analogue of etomidate‏
670 ‎‡a  Author's Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes‏
670 ‎‡a  Author's Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization‏
670 ‎‡a  Author's Screening active components of modified Xiaoyao powder as NRF2 agonists.‏
670 ‎‡a  Author's Simultaneous determination of tandospirone and its active metabolite, 1-[2-pyrimidyl]-piperazine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study‏
670 ‎‡a  Author's Tanshinone IIA prevents rifampicin-induced liver injury by regulating BSEP/NTCP expression via epigenetic activation of NRF2‏
670 ‎‡a  Author's UPLC-MS/MS method for the determination of tobacco-specific biomarker NNAL, tamoxifen and its main metabolites in rat plasma‏
909 ‎‡a  (orcid) 0000000332206065‏ ‎‡9  1‏
919 ‎‡a  uplcmsmsmethodforthedeterminationoftobaccospecificbiomarkernnaltamoxifenanditsmainmetabolitesinratplasma‏ ‎‡A  UPLC-MS/MS method for the determination of tobacco-specific biomarker NNAL, tamoxifen and its main metabolites in rat plasma‏ ‎‡9  1‏
919 ‎‡a  physiologicallybasedpharmacokineticmodelingofoxycodoneinchildrentosupportpediatricdosingoptimization‏ ‎‡A  Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization‏ ‎‡9  1‏
919 ‎‡a  screeningactivecomponentsofmodifiedxiaoyaopowderasnrf2agonists‏ ‎‡A  Screening active components of modified Xiaoyao powder as NRF2 agonists.‏ ‎‡9  1‏
919 ‎‡a  simultaneousdeterminationoftandospironeanditsactivemetabolite1piperazineinratplasmabylcmsmsanditsapplicationtoapharmacokineticstudy‏ ‎‡A  Simultaneous determination of tandospirone and its active metabolite, 1-[2-pyrimidyl]-piperazine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study‏ ‎‡9  1‏
919 ‎‡a  tanshinoneiiapreventsrifampicininducedliverinjurybyregulatingbsepntcpexpressionviaepigeneticactivationofnrf2‏ ‎‡A  Tanshinone IIA prevents rifampicin-induced liver injury by regulating BSEP/NTCP expression via epigenetic activation of NRF2‏ ‎‡9  1‏
919 ‎‡a  comparisonsofpharmacokineticsandnoreleasingofnitrofibriateandfenofibrateafteroraladministrationinrats‏ ‎‡A  Comparisons of pharmacokinetics and NO-releasing of nitrofibriate and fenofibrate after oral administration in rats‏ ‎‡9  1‏
919 ‎‡a  doseadjustmentofquetiapineandaripiprazoleforpregnantwomenusingphysiologicallybasedpharmacokineticmodelingandsimulation‏ ‎‡A  Dose Adjustment of Quetiapine and Aripiprazole for Pregnant Women Using Physiologically Based Pharmacokinetic Modeling and Simulation‏ ‎‡9  1‏
919 ‎‡a  enhancedcancertargeteddrugdeliveryusingprecoatednanoparticles‏ ‎‡A  Enhanced Cancer-targeted Drug Delivery Using Precoated Nanoparticles‏ ‎‡9  1‏
919 ‎‡a  invitroandinsituassessmentoftheeffluxof5antidepressantsbybreastcancerresistanceprotein‏ ‎‡A  In-vitro and in situ assessment of the efflux of five antidepressants by breast cancer resistance protein‏ ‎‡9  1‏
919 ‎‡a  metaboliteidentificationtissuedistributionexcretionandpreclinicalpharmacokineticstudiesofet26hclanewanalogueofetomidate‏ ‎‡A  Metabolite identification, tissue distribution, excretion and preclinical pharmacokinetic studies of ET-26-HCl, a new analogue of etomidate‏ ‎‡9  1‏
919 ‎‡a  physiologicallybasedpharmacokineticmodelingofbrivaracetamanditsinteractionswithrifampinbasedoncyp2c19phenotypes‏ ‎‡A  Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes‏ ‎‡9  1‏
996 ‎‡2  ISNI|0000000064319206‏
996 ‎‡2  LC|no2014053945‏
996 ‎‡2  CYT|AC000007535‏
996 ‎‡2  SUDOC|030140285‏
996 ‎‡2  SUDOC|175823545‏
996 ‎‡2  CYT|AC000256146‏
996 ‎‡2  LC|n 81070599‏
996 ‎‡2  CYT|AC000657655‏
996 ‎‡2  ISNI|0000000063422519‏
996 ‎‡2  DNB|103141214X‏
996 ‎‡2  ISNI|0000000077143916‏
996 ‎‡2  DNB|172792746‏
996 ‎‡2  SUDOC|162018053‏
996 ‎‡2  CYT|AC000642135‏
996 ‎‡2  LC|n 2023062886‏
996 ‎‡2  LC|no2011120797‏
996 ‎‡2  CYT|AC000399448‏
996 ‎‡2  KRNLK|KAC200509607‏
996 ‎‡2  ISNI|000000006424665X‏
996 ‎‡2  LC|n 2017037158‏
996 ‎‡2  NYNYRILM|45480‏
996 ‎‡2  LC|no2017019498‏
996 ‎‡2  NUKAT|n 2007003004‏
996 ‎‡2  DNB|1048037029‏
996 ‎‡2  DNB|13234646X‏
996 ‎‡2  RERO|A018080334‏
996 ‎‡2  DNB|1136573305‏
996 ‎‡2  LC|n 94802049‏
996 ‎‡2  SZ|1136573305‏
996 ‎‡2  RERO|A012862856‏
996 ‎‡2  LC|n 80020002‏
996 ‎‡2  CYT|AC000400547‏
996 ‎‡2  NTA|153366095‏
996 ‎‡2  CYT|AC000641516‏
996 ‎‡2  J9U|987007446406105171‏
996 ‎‡2  LC|n 85362381‏
996 ‎‡2  NII|DA09064192‏
996 ‎‡2  LC|nr 95036309‏
996 ‎‡2  NSK|000754545‏
996 ‎‡2  SUDOC|261161946‏
996 ‎‡2  LC|nr 98016881‏
996 ‎‡2  ISNI|0000000064234616‏
996 ‎‡2  LC|no2022006566‏
996 ‎‡2  CYT|AC000594207‏
996 ‎‡2  NTA|364154152‏
996 ‎‡2  ISNI|0000000074972866‏
996 ‎‡2  CYT|AC000661662‏
996 ‎‡2  NUKAT|n 02046296‏
996 ‎‡2  LC|nb2014019793‏
996 ‎‡2  CYT|AC000347641‏
996 ‎‡2  ISNI|0000000064106980‏
996 ‎‡2  ISNI|0000000063920956‏
996 ‎‡2  DNB|139137688‏
996 ‎‡2  CYT|AC000632051‏
996 ‎‡2  CAOONL|ncf10474994‏
996 ‎‡2  NTA|364154683‏
996 ‎‡2  LC|n 79094355‏
996 ‎‡2  NDL|01034195‏
996 ‎‡2  LC|no2021053086‏
996 ‎‡2  LNB|LNC10-000144393‏
996 ‎‡2  CYT|AC000209082‏
996 ‎‡2  NII|DA00943117‏
996 ‎‡2  DNB|1203162073‏
996 ‎‡2  ISNI|0000000383322517‏
996 ‎‡2  ISNI|0000000063353453‏
996 ‎‡2  ISNI|0000000037830543‏
996 ‎‡2  CAOONL|ncf11530748‏
996 ‎‡2  BNF|14539365‏
996 ‎‡2  DNB|120843702X‏
996 ‎‡2  NKC|xx0215777‏
996 ‎‡2  DNB|1157266843‏
996 ‎‡2  CYT|AC000256017‏
996 ‎‡2  CYT|AC000009568‏
996 ‎‡2  NUKAT|nx2023110838‏
996 ‎‡2  PLWABN|9810552180705606‏
996 ‎‡2  ISNI|0000000069723267‏
996 ‎‡2  BIBSYS|6068356‏
996 ‎‡2  SUDOC|272335371‏
996 ‎‡2  PLWABN|9811552473905606‏
996 ‎‡2  ISNI|0000000500699453‏
996 ‎‡2  DNB|1330948831‏
996 ‎‡2  ISNI|0000000362686960‏
996 ‎‡2  LC|n 84027413‏
996 ‎‡2  CAOONL|ncf11882034‏
996 ‎‡2  DNB|1141802414‏
996 ‎‡2  DNB|125802182X‏
996 ‎‡2  ISNI|0000000054203103‏
996 ‎‡2  LC|n 85064938‏
996 ‎‡2  LC|n 2017045475‏
996 ‎‡2  NII|DA10444907‏
996 ‎‡2  DNB|1177151189‏
996 ‎‡2  ISNI|0000000087584440‏
996 ‎‡2  LC|nr 92016086‏
996 ‎‡2  CYT|AC000204560‏
996 ‎‡2  ISNI|0000000028390443‏
996 ‎‡2  ISNI|0000000439813631‏
996 ‎‡2  LC|no2017079105‏
996 ‎‡2  CYT|AC000400549‏
996 ‎‡2  CYT|AC000400548‏
996 ‎‡2  DNB|1218497432‏
996 ‎‡2  DNB|1268138061‏
996 ‎‡2  DNB|13804676X‏
996 ‎‡2  DNB|122211979‏
996 ‎‡2  DNB|1158211155‏
996 ‎‡2  DNB|1296455319‏
996 ‎‡2  DNB|1019162902‏
996 ‎‡2  CYT|AC000642454‏
996 ‎‡2  ISNI|0000000063607134‏
996 ‎‡2  DNB|1229127259‏
996 ‎‡2  ISNI|0000000063491960‏
996 ‎‡2  LC|n 2013049715‏
996 ‎‡2  NTA|118519336‏
996 ‎‡2  CYT|AC000257218‏
996 ‎‡2  NYNYRILM|251222‏
996 ‎‡2  ISNI|0000000381728898‏
996 ‎‡2  CYT|AC000653417‏
996 ‎‡2  W2Z|6068356‏
996 ‎‡2  BNF|16259145‏
996 ‎‡2  ISNI|000000006383525X‏
996 ‎‡2  BNF|17178947‏
996 ‎‡2  NUKAT|n 2014061020‏
996 ‎‡2  BAV|495_222596‏
996 ‎‡2  LC|nr 95035433‏
996 ‎‡2  J9U|987007416012605171‏
996 ‎‡2  DNB|1323290753‏
996 ‎‡2  LC|n 87844440‏
996 ‎‡2  DNB|115821619X‏
996 ‎‡2  DNB|1030066043‏
996 ‎‡2  ISNI|0000000116901274‏
996 ‎‡2  ISNI|0000000388284740‏
996 ‎‡2  LC|n 2006222380‏
996 ‎‡2  CYT|AC000642326‏
996 ‎‡2  B2Q|0001206782‏
996 ‎‡2  NII|DA12212640‏
996 ‎‡2  CYT|AC000634407‏
996 ‎‡2  LC|nr 00005357‏
996 ‎‡2  LC|n 2021050544‏
996 ‎‡2  NTA|183136020‏
996 ‎‡2  SUDOC|264058518‏
996 ‎‡2  ISNI|0000000498767655‏
996 ‎‡2  LC|n 2004101983‏
996 ‎‡2  LC|n 2010007494‏
996 ‎‡2  DNB|1033149780‏
996 ‎‡2  ISNI|0000000063811901‏
996 ‎‡2  DNB|1294223976‏
996 ‎‡2  LC|nr 93005063‏
996 ‎‡2  LC|ns2011000517‏
996 ‎‡2  LC|nr 95000153‏
996 ‎‡2  DNB|133180816‏
996 ‎‡2  LC|n 2011185670‏
996 ‎‡2  DNB|1153569027‏
996 ‎‡2  ISNI|0000000008559598‏
996 ‎‡2  ISNI|0000000012794021‏
996 ‎‡2  ISNI|0000000360213780‏
996 ‎‡2  DNB|1254571353‏
996 ‎‡2  J9U|987007269503105171‏
996 ‎‡2  DNB|117468996X‏
996 ‎‡2  RERO|A003957507‏
996 ‎‡2  NSK|000704850‏
996 ‎‡2  LC|no2009199718‏
996 ‎‡2  NSK|000337340‏
996 ‎‡2  LC|n 2017075168‏
996 ‎‡2  LC|no2010175360‏
996 ‎‡2  SUDOC|081577990‏
996 ‎‡2  J9U|987007317384505171‏
996 ‎‡2  DNB|1148800212‏
996 ‎‡2  LC|n 91049234‏
996 ‎‡2  ISNI|0000000073370863‏
996 ‎‡2  BIBSYS|7064331‏
996 ‎‡2  ISNI|0000000064267610‏
996 ‎‡2  LC|no2019117553‏
996 ‎‡2  J9U|987007439870605171‏
996 ‎‡2  DNB|1178546489‏
996 ‎‡2  SUDOC|193825066‏
996 ‎‡2  LC|no2008074319‏
996 ‎‡2  BNF|12161610‏
996 ‎‡2  LC|n 98075034‏
996 ‎‡2  LC|n 92107826‏
996 ‎‡2  LC|n 80025547‏
996 ‎‡2  SUDOC|191453803‏
996 ‎‡2  ISNI|0000000063144096‏
996 ‎‡2  NII|DA1510818X‏
996 ‎‡2  NTA|340412437‏
996 ‎‡2  CYT|AC000634633‏
996 ‎‡2  LC|no2010175364‏
996 ‎‡2  PTBNP|41206‏
996 ‎‡2  DNB|1242737758‏
996 ‎‡2  PLWABN|9810558167005606‏
996 ‎‡2  ISNI|0000000040116092‏
996 ‎‡2  RERO|A000175034‏
996 ‎‡2  ISNI|0000000049945866‏
996 ‎‡2  BNF|15878306‏
996 ‎‡2  ISNI|000000043684263X‏
996 ‎‡2  ISNI|0000000498377286‏
996 ‎‡2  LC|n 81098778‏
996 ‎‡2  NSK|000526804‏
996 ‎‡2  DNB|1263789889‏
996 ‎‡2  ISNI|0000000381642170‏
996 ‎‡2  LC|n 2003103998‏
996 ‎‡2  BIBSYS|90217323‏
996 ‎‡2  BNC|981058520419206706‏
996 ‎‡2  DNB|1311564020‏
996 ‎‡2  DNB|1156751640‏
996 ‎‡2  CYT|AC000659502‏
996 ‎‡2  ISNI|000000049808255X‏
996 ‎‡2  NTA|188459634‏
996 ‎‡2  LC|nr 98025322‏
996 ‎‡2  LC|n 85213297‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏